Replimune (REPL) Common Equity (2018 - 2026)
Replimune (REPL) posted Common Equity of $166.2 million for Q1 2026, down 21.08% sequentially from $210.5 million in Q4 2025, and down 60.04% YoY from $415.8 million in Q1 2025.
Replimune (REPL) Common Equity (2018 - 2026) Analysis & Trends
Replimune has reported Common Equity for 9 years, with the latest figure at $166.2 million in Q1 2026.
- Quarterly Common Equity fell 60.04% year-over-year to $166.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $166.2 million (down 60.04% YoY) and the FY2026 annual result came in at $166.2 million, down 60.04% from the prior year.
- Common Equity retreated to $166.2 million in Q1 2026 per REPL's latest filing, from $210.5 million in the prior quarter.
- Over five years, Common Equity peaked at $595.3 million in Q4 2022 and troughed at $166.2 million in Q1 2026.
- A 5-year average of $400.8 million and a median of $411.2 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2026: Common Equity surged 36.08% in 2022, then plunged 60.04% in 2026.
- Over 5 years, Common Equity stood at $595.3 million in 2022, then dropped by 29.19% to $421.5 million in 2023, then grew by 14.43% to $482.4 million in 2024, then slumped by 56.35% to $210.5 million in 2025, then declined by 21.08% to $166.2 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $166.2 million, $210.5 million, and $263.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | 166.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 166.16 Mn |
| Dec 31, 2025 | 210.54 Mn |
| Sep 30, 2025 | 263.34 Mn |
| Jun 30, 2025 | 336.72 Mn |
| Mar 31, 2025 | 415.84 Mn |
| Dec 31, 2024 | 482.37 Mn |
| Sep 30, 2024 | 381.46 Mn |
| Jun 30, 2024 | 426.45 Mn |
| Mar 31, 2024 | 374.51 Mn |
| Dec 31, 2023 | 421.54 Mn |
| Sep 30, 2023 | 465.17 Mn |
| Jun 30, 2023 | 514.03 Mn |
| Mar 31, 2023 | 555.29 Mn |
| Dec 31, 2022 | 595.35 Mn |
| Sep 30, 2022 | 384.07 Mn |
| Jun 30, 2022 | 410.26 Mn |
| Mar 31, 2022 | 411.23 Mn |
| Dec 31, 2021 | 437.51 Mn |
| Sep 30, 2021 | 457.41 Mn |
| Jun 30, 2021 | 479.02 Mn |